Ein tibetisches Kombinationspräparat bei peripherer arterieller Verschlusskrankheit

Zusammenfassung

Padma® 28 ist ein tibetisches Kombinationspräparat, das in der Schweiz nach einer traditionellen Rezeptur hergestellt wird. Es bietet einen wirksamen und klinisch relevanten Behandlungsansatz in den frühen Stadien der peripheren arteriellen Verschlusskrankheit. Dies zeigt eine Metaanalyse mit 5 klinischen Studien bei Patienten mit Claudicatio intermittens. Die Gehstrecke konnte unter Verumbehandlung signifikant verlängert werden. Lesen Sie, welche weiteren Ergebnisse in der Analyse herausgefunden werden konnten und welche Wirkprinzipien zugrunde liegen.

Schlüsselwörter

periphere arterielle Verschlusskrankheit - PAVK - Atherosklerose - Claudicatio intermittens - Phytotherapie - Tibetische Medizin - pleiotrop - Multi-Target-Mechanismus

• Literatur

• 1 Hankey GJ. Vascular disease of the heart, brain and limbs: new insights into a looming epidemic. Lancet 2005; 366: 1753-1754
• 2 Rothwell PM, Coull AJ, Silver LE et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366: 1773-1783
• 3 Andersson KE, Hellstrand P. Dietary oats and modulation of atherogenic pathways. Mol Nutr Food Res 2012;
• 4 Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther 2011; 5: 325-380
• 5 OʼKeefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc 2009; 84: 741-757
• 6 McDermott MM. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med 2006; 73 (Suppl. 04) S2-S7
• 7 Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159: 337-345
• 8 Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2008; (4) CD000990
• 9 De Backer T, Vander Stichele R, Lehert P et al. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. BMJ 2009; 338: b603
• 10 Thompson PD, Zimet R, Forbes WP et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90: 1314-1319
• 11 Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008; (1) CD003748
• 12 Shahin Y, Mazari F, Chetter I. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials. Int J Surg 2011; 9: 209-213
• 13 Zeng Y, Song JX, Shen XC. Herbal remedies supply a novel prospect for the treatment of atherosclerosis: a review of current mechanism studies. Phytother Res 2012; 26: 159-167
• 14 Team V, Canaway R, Manderson L. Integration of complementary and alternative medicine information and advice in chronic disease management guidelines. Aust J Prim Health 2011; 17: 142-149
• 15 Grant SJ, Yu SB, Kiat H et al. The use of complementary and alternative medicine by people with cardiovascular disease: a systematic review. BMC Public Health 2012; 12: 299
• 16 Widrig R, Suter A, Saller R, Melzer J. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int 2007; 27: 585-591
• 17 Melzer J, Rosch W, Reichling J et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 1279-1287
• 18 Melzer J, Brignoli R, Diehm C et al. Treating intermittent claudication with Tibetan medicine Padma 28: does it work?. Atherosclerosis 2006; 189: 39-46
• 19 Saller R. Tibetan remedies in chronic disease. Forsch Komplementmed 2006; 13 (Suppl. 01) VII-VIII
• 20 Schmermund A, Erbel R. Therapie der Arteriosklerose. Dtsch Med Wochenschr 2003; 128: 41-47
• 21 Rutishauser J. Pleiotrope Statineffekte. Schweiz Med Forum 2008; 8: 187-190
• 22 Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: anoverview. Free Radic Biol Med 2000; 28: 1815-1826
• 23 Lönn ME, Dennis JM, Stocker R. Actions of “antioxidants” in the protection against atherosclerosis. Free Radic Biol Med 2012; [Epub ahead of print]
• 24 Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res 2012; [Epub ahead of print]
• 25 Yiannakopoulou EC. Does pharmacodynamic interaction of nonenzymatic antioxidants modify response to antioxidant therapy in the process of atherosclerosis?. J Cardiovasc Pharmacol Ther 2012; [Epub ahead of print]
• 26 Dowling JK, OʼNeill LA. Biochemical regulation of the inflammasome. Crit Rev Biochem Mol Biol 2012; [Epub ahead of print]
• 27 Ueberall F, Fuchs D, Vennos C. Anti-inflammatory potential of Padma 28 – review of experimental data on the antiatherogenic activity and discussion of the multi-component principle. Forsch Komplementmed 2006; 13 (Suppl. 01) S7-S12
• 28 Fuentes QE, Fuentes QF, Andrés V et al. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 2012; [Epub ahead of print]
• 29 Exner M, Raith M, Holzer G et al. Anti-inflammatory mechanisms of the Tibetan herbal preparation Padma 28 in the vessel wall. Forsch Komplementmed 2006; 13 (Suppl. 01) S13-S17
• 30 Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005; 26: 178-182
• 31 Espinoza-Fonseca LM. The benefits of the multi-target approach in drug design and discovery. Bioorg Med Chem 2006; 14: 896-897
• 32 Yu H, Chen J, Xu X et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 2012; 7: e37608
• 33 Faxon DP, Creager MA, Smith Jr SC et al. Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2004; 109: 2595-2604
• 34 Diehm C, Schuster A, Allenberg JR et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172: 95-105
• 35 De Backer TL, Vander Stichele RH, Warie HH et al. Oral vasoactive medication in intermittent claudication: useful or futile?. Eur J Clin Pharmacol 2000; 56: 199-206
• 36 European Stroke Organisation. SC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851-2906
• 37 Nicolai SP, Kruidenier LM, Bendermacher BL et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2009; (2) CD006888
• 38 Rodríguez M, Ringstad L, Schäfer P et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis 2007; 192: 438-444
• 39 Siegel G, Schäfer P, Winkler K et al. Ginkgo biloba (EGb 761) in arteriosclerosis prophylaxis. Wien Med Wochenschr 2007; 157: 288-294
• 40 Jung IH, Lee YH, Yoo JY et al. Ginkgo biloba extract (GbE) enhances the anti-atherogenic effect of cilostazol by inhibiting ROS generation. Exp Mol Med 2012; 44: 311-318